Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women

Aromatase, encoded by the CYP19A1 gene, is a key enzyme in estradiol biosynthesis, which catalyzes the conversion of androstenedione and testosterone to estrone and estradiol, respectively. Given the critical role of estrogen in the development of endometrial cancer risk, we evaluated genetic polymorphisms of the CYP19A1 gene, including rs1065779, rs700519, rs28566535, rs752760, and rs1870050, in association with endometrial cancer in a population-based case-control study conducted in Shanghai, China. Genotypes of 1,040 incident endometrial cancer cases and 1,031 frequency-matched controls were included in the study. We applied a logistic regression model to derive adjusted odds ratios (OR) and their 95% confidence intervals (95% CI). Six common haplotypes with a frequency ≥5% were estimated; the highest frequency haplotype was GCACA (27.8% in cases and 26.2% in controls). We observed an inverse association between CYP19A1 haplotype TCATC and endometrial cancer in our population (OR, 0.76; 95% CI, 0.62-0.92). An inverse association was found between endometrial cancer and single nucleotide polymorphism rs1870050 in the promoter region with ORs of 0.81 (95% CI, 0.68-0.97) and 0.58 (95% CI, 0.42-0.80) for the AC and CC genotypes, respectively. We observed a multiplicative interaction between single nucleotide polymorphism rs700519 and body mass index among postmenopausal women (P = 0.01), with stronger associations between rs700519 genotypes and endometrial cancer risk among heavier (body mass index, ≥25) postmenopausal women. In summary, our data show that polymorphisms in the CYP19A1 gene may contribute to endometrial carcinogenesis. (Cancer Epidemiol Biomarkers Prev 2007;16(5):943–9)

[1]  J. Long,et al.  CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women , 2007, International Journal of Obesity.

[2]  X. Shu,et al.  Functional Ser326Cys Polymorphism in the hOGG1 Gene Is Not Associated with Breast Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[3]  Eric D Wieben,et al.  Human aromatase: gene resequencing and functional genomics. , 2005, Cancer research.

[4]  G. Colditz,et al.  CYP19 (aromatase) haplotypes and endometrial cancer risk , 2005, International journal of cancer.

[5]  B. Ponder,et al.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women. , 2005, Journal of the National Cancer Institute.

[6]  J. Witte,et al.  No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  A. Whittemore,et al.  Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study , 2004, Breast Cancer Research.

[8]  K. Matsuo,et al.  The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  Georg Heinze,et al.  Estrogen‐metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women , 2004, Cancer.

[10]  T. Araki,et al.  Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. , 2004, Anticancer research.

[11]  A. Folsom,et al.  CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. , 2004, Cancer letters.

[12]  F. Berrino,et al.  Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women , 2004, International journal of cancer.

[13]  Y. Miyoshi,et al.  Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. , 2003, European journal of cancer.

[14]  Malcolm C Pike,et al.  A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. , 2003, Human molecular genetics.

[15]  Kazuto Ito,et al.  Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol‐O‐methyltransferase are associated with familial prostate carcinoma risk in a Japanese population , 2003, Cancer.

[16]  E. Simpson.  Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  Takashi Suzuki,et al.  The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  D. Noh,et al.  Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women , 2003, British Journal of Cancer.

[19]  R. Kaaks,et al.  Obesity , Endogenous Hormones , and Endometrial Cancer Risk : A Synthetic Review 1 , 2002 .

[20]  G. Séralini,et al.  Aromatase and breast cancer: W39R, an inactive protein. , 2002, European journal of endocrinology.

[21]  T. Yoshikawa,et al.  Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. , 2002, Human reproduction.

[22]  S. Bulun,et al.  Estrogen production and action. , 2001, Journal of the American Academy of Dermatology.

[23]  A. Zeleniuch‐Jacquotte,et al.  Role of Exogenous and Endogenous Hormones in Endometrial Cancer , 2001, Annals of the New York Academy of Sciences.

[24]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[25]  R. Shore,et al.  Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study , 2001, British Journal of Cancer.

[26]  E. Imyanitov,et al.  CYP19 gene polymorphism in endometrial cancer patients , 2001, Journal of Cancer Research and Clinical Oncology.

[27]  Y. Miyoshi,et al.  Breast cancer risk associated with polymorphism in CYP19 in Japanese women , 2000, International journal of cancer.

[28]  H. Sasano,et al.  Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. , 1999, Endocrine-related cancer.

[29]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[30]  O. Gotoh,et al.  Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. , 1997, Pharmacogenetics.

[31]  S. Bulun,et al.  Endocrine disorders associated with inappropriately high aromatase expression , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  R. Hoover,et al.  Case-control study of endogenous steroid hormones and endometrial cancer. , 1996, Journal of the National Cancer Institute.

[33]  C. Mendelson,et al.  Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. , 1995, Molecular endocrinology.

[34]  N. Harada,et al.  Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. , 1995, The American journal of pathology.

[35]  D. Miller,et al.  CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[36]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[37]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Hagen,et al.  Plasma oestrogens in postmenopausal women with endometrial cancer , 1993, British journal of obstetrics and gynaecology.

[39]  L. Berstein,et al.  CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. , 2005, Neoplasma.